Robert E. Winkler
Keine laufenden Positionen mehr
Profil
Robert E.
Winkler worked as Vice President of Clinical Research & Development at Array BioPharma, Inc. He then worked as Vice President of Clinical Research & Operations at Amicus Therapeutics, Inc. from 2011 to 2013.
In 2018, he became the Chief Medical Officer at Zentalis Pharmaceuticals, Inc. Dr. Winkler received his undergraduate and doctorate degrees from The Hebrew University Hadassah Medical School.
Ehemalige bekannte Positionen von Robert E. Winkler
Unternehmen | Position | Ende |
---|---|---|
ZENTALIS PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 19.03.2020 |
AMICUS THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2013 |
ARRAY TECHNOLOGIES, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Robert E. Winkler
The Hebrew University Hadassah Medical School | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
AMICUS THERAPEUTICS, INC. | Health Technology |
ZENTALIS PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Array BioPharma, Inc.
Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |